Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C

BACKGROUND: US Food and Drug Administration (FDA) set a rigorous standard for defining patient responders in irritable bowel syndrome-C (IBS-C; i.e., FDA's Responder Endpoint) for regulatory approval. However, this endpoint's utility for health-care practitioners to assess clinical respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacy, B E, Lembo, A J, MacDougall, J E, Shiff, S J, Kurtz, C B, Currie, M G, Johnston, J M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282394/
https://www.ncbi.nlm.nih.gov/pubmed/24382134
http://dx.doi.org/10.1111/nmo.12264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282394/
https://www.ncbi.nlm.nih.gov/pubmed/24382134
http://dx.doi.org/10.1111/nmo.12264

Ejemplares similares